Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Memphasys Ltd ( (AU:MEM) ) is now available.
Memphasys Limited has signed a transformative five-year exclusive distribution agreement with International Technical Legacy (ITL) for its Felix™ sperm preparation system across 15 countries in the Middle East and North Africa. This partnership, which includes an initial order valued at A$325,000 contingent on CE Mark approval, positions Memphasys to access a market with approximately 140,000 IVF cycles annually. The agreement ensures rapid adoption through ITL’s established presence and expertise, and it includes provisions for future reproductive technologies. Memphasys is also pursuing similar agreements in other regions, aiming to generate immediate cash flows and diversify revenue streams, thereby de-risking its broader rollout strategy.
More about Memphasys Ltd
Memphasys Limited is a company involved in the reproductive technology industry, focusing on products like the Felix™ male fertility sperm preparation system. The company aims to enhance fertility treatment outcomes and has a market focus that includes regions such as the Middle East, North Africa, New Zealand, Japan, and India.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.94M
Find detailed analytics on MEM stock on TipRanks’ Stock Analysis page.